CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase (HMT) inhibition in human cancers at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Mass., November 5 – 9, 2015. Among the presentations are important new data on the critical role played by EZH2 in Non-Hodgkin Lymphoma (NHL). Epizyme’s lead compound, tazemetostat, is a first-in-class EZH2 inhibitor currently being studied in relapsed or refractory B-cell NHL and advanced solid tumors.
Help employers find you! Check out all the jobs and post your resume.
